Paromomycin sulfate: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 20: | Line 20: | ||
'''| [[Paromomycin sulfate warnings and precautions|Warnings and Precautions]]''' | '''| [[Paromomycin sulfate warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[Paromomycin sulfate adverse reactions|Adverse Reactions]]''' | '''| [[Paromomycin sulfate adverse reactions|Adverse Reactions]]''' | ||
'''| [[Paromomycin sulfate clinical studies|Clinical Studies]]''' | '''| [[Paromomycin sulfate clinical studies|Clinical Studies]]''' | ||
'''| [[Paromomycin sulfate dosage and administration|Dosage and Administration]]''' | '''| [[Paromomycin sulfate dosage and administration|Dosage and Administration]]''' |
Revision as of 20:34, 23 December 2013
Paromomycin Sulfate |
---|
PAROMOMYCIN SULFATE capsule® FDA Package Insert |
Description |
Clinical Pharmacology |
Indications and Usage |
Contraindications |
Warnings and Precautions |
Adverse Reactions |
Dosage and Administration |
How Supplied |
Labels and Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Paromomycin is an aminoglycoside antibiotic, first isolated from Streptomyces krestomuceticus in the 1950s.[1] It was discovered by Parke Davis now Pfizer and introduced as Humatin in 1960.[2] It is also called monomycin and aminosidine.[3]
Category
Amebicide
US Brand Names
PAROMOMYCIN SULFATE capsule®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanisms of Action
Paromomycin is a protein synthesis inhibitor in non-resistant cells by binding to 16S ribosomal RNA.[4] This broad spectrum antibiotic soluble in water, is very similar in action to Neomycin. Antimicrobial activity of Paromomycin against Escherichia coli and Staphylococcus aureus has been shown.[5]
References
- ↑ Davidson R.N., den Boer M., Ritmeijer K. (2008). "Paromomycin". Transactions of the Royal Society of Tropical Medicine and Hygiene. 103 (7): 653–60. doi:10.1016/j.trstmh.2008.09.008. PMID 18947845.
- ↑ Page 1166. http://books.google.co.in/books?id=XCsJgUnclbcC&pg=PA1257&dq=Pharmaceutical+Manufacturing+Encyclopedia,+Volume+2&hl=en&sa=X&ei=9V7iT8mqJoOIrAfe4P2zAw&ved=0CDoQ6AEwAA#v=onepage&q=Pharmaceutical%20Manufacturing%20Encyclopedia%2C%20Volume%202&f=false
- ↑ Neal R.A.; et al. (1994). "Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis". Transactions of the Royal Society of Tropical Medicine and Hygiene. 88 (2): 223–5. doi:10.1016/0035-9203(94)90307-7. PMID 8036682.
- ↑ Vicens, Quentin (2001). "Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site". Structure. 9 (8): 647–658. doi:10.1016/S0969-2126(01)00629-3. PMID 11587639. Retrieved 2007-02-10. Unknown parameter
|month=
ignored (help); Unknown parameter|coauthors=
ignored (help) - ↑ "Paromomycin" (pdf). Toku-E. 2010-01-12. Retrieved 2012-06-11.